1431368-48-7

1431368-48-7 structure

Name: GSK-LSD1 2HCL
Chemical Name: N-[(1R,2S)-2-Phenylcyclopropyl]-4-piperidinamine
CAS Number: 1431368-48-7
Molecular Formula: C₁₄H₂₀N₂
Molecular Weight: 216.322
Catalog: Biochemical Inhibitor Epigenetics Histone Demethylase Inhibitor
Create Date: 2018-01-20 12:33:26
Modify Date: 2025-08-31 19:47:30
GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3].

Name	N-[(1R,2S)-2-Phenylcyclopropyl]-4-piperidinamine
Synonyms	N-[(1R,2S)-2-Phenylcyclopropyl]-4-piperidinamine 4-Piperidinamine, N-[(1R,2S)-2-phenylcyclopropyl]- GSK-LSD1 2HCL GSK-LSD1 (hydrochloride) LSD1 inhibitor

Description	GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3].
Related Catalog	Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> Epigenetics >> Histone Demethylase Research Areas >> Metabolic Disease
References	[1]. Ramms B, et al. Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes. 2022 Dec 1;71(12):2513-2529. [2]. Hong KS, et al. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. Signal Transduct Target Ther. 2020 Nov 17;5(1):267. [3]. Alsaqer SF, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8(43):73372-73386.